Natco Pharma has filed Abbreviated New Drug Applications (ANDAs) for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, with the US Federal Drug Administration (US FDA), through its respective marketing partners in the USA.
Natco & its associated marketing partners, for the above products in the USA, are the first company to have filed a substantially complete ANDA which includes a paragraph IV certification for Fingolimod, 0.5mg Capsules & Cabazitaxel, 60mg/1.5ml Injection, providing 180 days of marketing exclusivity upon its final US FDA approval.
Novartis sells Fingolimod 0.5mg Capsules under Brand name Gilenya, in the USA market and used for the treatment of certain patients with multiple sclerosis. The market size of Gilenya in the USA is around $1.2 billion for twelve months ending September 2014.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.60 |
| Dr. Reddys Lab | 1232.65 |
| Cipla | 1242.10 |
| Zydus Lifesciences | 944.25 |
| Lupin | 2328.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: